# YI earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/YI) · [Earnings tab](https://www.lopjlb.com/stock/YI?tab=earnings) Updated: 2026-08-20T05:41:33 Quarters analyzed: 8 ## Cross-quarter narrative From mid‑2023 through early 2025, 111 Inc. (YI) transitioned from top‑line growth with expanding losses to flat revenue but first‑time operational profit and positive cash flow. Early calls highlighted 14% YoY growth, digital partnerships (Tencent), private‑label launches, and a pending go‑private process. By late 2023, growth slowed to ~9.5% as inventory digestion and competition pressured gross margins, while operating expense ratios improved. The 2023 Q4 call showed FY revenue up 10.6% but Q4 flat, with JBP segment reaching ~60% of sales and non‑GAAP operating loss narrowing to 0.8% of revenue. In 2024, management emphasized profitability: Q2 delivered operational profit via expense reductions and logistics expansion; Q3 maintained profit despite flat revenue, cutting operating expenses to 5.8% of revenue; Q4 achieved full‑year operational profit and positive cash flow, driven by aggressive cost cuts and AI‑enabled efficiency. Throughout, capital allocation shifted toward the Kunpeng logistics network, AI tools (forecasting, catalog, price index), and fulfillment center rollouts. Persistent fears include macroeconomic weakness, regulatory/anti‑corruption reforms, competitive pharmacy overcapacity, and redemption/debt obligations (RMB1.08 bn loan). The privatization overhang faded after 2023 Q3, while new risks emerged around AI execution and uneven policy implementation. ## Latest CallCard · Q4 111 posted its first operational profit and positive cash flow in 2024, cut operating expenses sharply, expanded AI‑driven logistics, and sees long‑term demand despite macro headwinds. **Guidance:** vague — Management expressed optimism for 2025 but provided no specific revenue or margin guidance. **Tone:** mgmt 0.8 · Q&A pressure 0.5 · divergence 0.3 Prepared remarks highlighted operational profitability, cash flow positivity and confidence in AI‑driven efficiency as evidence of optimism. ### Demand visibility Demand faces macro headwinds but long‑term growth is expected from aging population and policy reforms. Cautious consumer spending and slower healthcare expenditure dampen short‑term sales, while anti‑corruption reforms and an aging demographic are seen as structural tailwinds. ### Margins / costs Margins improved through aggressive cost cuts and AI‑enabled efficiency. Operating expense ratio fell to 5.5% of revenue, fulfillment costs trimmed, and AI forecasting boosted gross margin while maintaining competitive pricing. ### Capital allocation Capital is being directed to AI, logistics network expansion and technology upgrades while preserving cost discipline. Investments include the Kunpeng Network, AI platforms (JVP, Borguan catalog), new fulfillment centers, and AI‑driven pricing and customer service tools. ### Milestones - **Kunpeng Network expansion** [on_track]: Added 7 new fulfillment centers and 28 routes, aiming for national coverage and faster delivery. - **AI powered Borguan catalog** [on_track]: Improved forecasting accuracy to 82% and introduced 6,598 new products, boosting GMV. - **AI forecasting accuracy improvement** [delivered]: Forecasting accuracy rose from 71% to 82%. - **AI powered price index tool** [new]: Planned for 2025 to optimize pricing strategies. - **Growing Together program** [on_track]: Launched to increase share‑of‑wallet with chain‑store customers. - **Flash sales events** [delivered]: December GMV up 17% and ARPU up 18% from targeted promotions. - **AI powered customer service** [new]: Development underway to reduce service staff via AI chat agents. - **Supply chain financing service** [new]: Introduced as a new revenue stream to support partners. ### Fears / risks - **Macroeconomic slowdown**: Cautious consumer behavior and reduced discretionary spending dampen retail sales. - **Regulatory reforms**: Uneven rollout of healthcare reforms creates uncertainty and potential cost pressures. - **Competitive pressure**: Aggressive store openings lead to overcapacity and margin compression. - **Debt repayment**: Redeemable loan of RMB1.08 bn and arbitration could affect cash flow. - **AI implementation risk**: Heavy reliance on AI for efficiency may face execution or adoption challenges. - **Supply chain disruptions**: Dependence on logistics network expansion could encounter operational hiccups. ### Key quotes > “we delivered our first ever operational profitability and positive operating cash flow, an important milestone in our company's history.” > “These improvements position us to better meet future demand with greater speed and lower costs, ultimately driving value across the industry.” > “we have achieved first half of annual operating profit and positive cash flow in 2024 on a whole year basis.” — Luke Chen > “we will definitely continue to utilize AI and our Internet technologies to continuously optimize their costs.” > “we slashed operating expenditure by 130 basis points to 5.3% of revenue, making us one of the most efficient operators in the industry.” ## Quarter one-liners - **2024 Q4:** 111 posted its first operational profit and positive cash flow in 2024, cut operating expenses sharply, expanded AI‑driven logistics, and sees long‑term demand despite macro headwinds. - **2024 Q3:** YI delivered flat Q3 revenue but maintained operating profit, cut costs, expanded digital and logistics networks amid macro headwinds and competitive pressure. - **2024 Q2:** 111 posted second‑quarter operational profit thanks to efficiency gains, digital upgrades and logistics expansion, while emphasizing profitability focus amid a challenging macro environment. - **2024 Q1:** — - **2023 Q4:** 111 Inc. Q4 revenue dipped 1% YoY to RMB4.1B on tough pandemic comparison; FY revenue grew 10.6% to RMB14.9B. Operating expenses rose in Q4 due to ESOP cancellation and severance, but full-year non-GAAP operating loss narrowed to 0.8% of revenue. JBP segment grew 25% YoY to ~60% of sales; private la - **2023 Q3:** 111 posted 9.5% YoY revenue growth to ¥3.7 bn, cut operating expense ratio to 7.4%, advanced digitization with new patents and AI, expanded JBP model, and is navigating inventory normalization, competition and a pending go‑private process. - **2023 Q2:** 111 posted 14% revenue growth and expanding margins in Q2 2023, highlighted digital partnerships and supply‑chain upgrades while noting policy shifts, competitive pressure and ongoing privatization risk. - **2023 Q1:** — ## Theme arcs - **Revenue Growth** (deteriorating): From 14% YoY (2023 Q2) to flat YoY (2024 Q3‑Q4); FY growth positive but quarterly momentum faded. - **Margin & Profitability** (improving): Operating expense ratio fell from ~7.4% to 5.8%; non‑GAAP operating loss narrowed to first operational profit and positive cash flow in 2024. - **Digital & AI Transformation** (improving): Progress from patents and Telescope SaaS to AI‑driven forecasting, catalog, price index, and herbal medicine model. - **Logistics & Fulfillment Expansion** (improving): Kunpeng network, new JV fulfillment centers (Wuhan, Guangzhou), warehouse‑to‑warehouse and last‑mile models delivered/on‑track. - **JBP & Private Label Growth** (improving): JBP segment grew to ~60% of sales; private label SKU expansion and third‑gen platform advancing. - **Regulatory & Macro Headwinds** (deteriorating): Anti‑corruption campaign, uneven policy rollout, weak consumer sentiment persist and intensify. - **Competitive Pressure** (stable): Pharmacy overcapacity, declining per‑store revenue, and margin compression cited consistently. - **Privatization / Go‑Private Process** (resolved): Prominent in 2023 Q2‑Q3; absent from 2024 calls, suggesting conclusion or deprioritization. - **Inventory Normalization** (resolved): Anti‑COVID inventory digestion noted in 2023 Q3‑Q4; not mentioned thereafter. ## Guidance path 2023 Q1:vague → 2023 Q2:maintained → 2023 Q3:vague → 2023 Q4:vague → 2024 Q1:vague → 2024 Q2:maintained → 2024 Q3:vague → 2024 Q4:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/YI`